# KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

> **NCT03925974** · PHASE2 · COMPLETED · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 45 (actual)

## Conditions studied

- Gastric/Gastroesophageal Junction Cancer

## Interventions

- **DRUG:** KN026 10 mg/kg QW
- **DRUG:** KN026 20 mg/kg Q2W
- **DRUG:** KN026 30 mg/kg Q3W

## Key facts

- **NCT ID:** NCT03925974
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-17
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03925974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03925974, "KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03925974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*